IP Library Granted Patent US 12,466,785
Granted Patent B2
US 12,466,785 · App. 18/002,941 · Granted Nov 11, 2025

Long-acting low-addiction HNK derivative and preparation method therefor

Inventors: Shu Peng Li (Oakville, CA); Qiang Zhou (San Francisco, CA)
Assignee: SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD
C07C229/60A61P25/24A61P25/28C07C227/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,785
App. No.
18/002,941
Granted
Nov 11, 2025
Kind
B2
Abstract

The present application relates to a compound having the effects of being an antidepressant, anesthetizing, alleviating pain, improving cognitive functions, protecting lungs, preventing or treating amyotrophic lateral sclerosis or preventing or treating complex regional pain syndrome. Compared with existing known HNK compounds, the compound provided in the present application has a longer drug efficacy period. Moreover the compound provided in the present application basically does not produce addiction.

Claims (26)

1 . A compound represented by Formula I, or a salt, stereoisomer or tautomer thereof:

wherein,

m is an integer from 0 to 3, and n is an integer from 0 to 4;

R 1 and R 2 are each independently one or more selected from a group consisting of H, halogen, hydroxyl, amino, cyano, substituted or unsubstituted C 1 -C 6 alkyl group, substituted or unsubstituted C 2 -C 6 alkenyl group, substituted or unsubstituted C 2 -C 6 alkynyl group, substituted or unsubstituted C 3 -C 10 cycloalkyl group, substituted or unsubstituted C 2 -C 10 heterocyclic group, substituted or unsubstituted C 1 -C 6 alkoxy group, substituted or unsubstituted mono- and di-C 1 -C 6 alkylamino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heteroaryl group;

R 3 is halogen;

R 4 is selected from a group consisting of H, substituted or unsubstituted C 1 -C 6 alkyl group, substituted or unsubstituted C 1 -C 8 acyl group, substituted or unsubstituted arylacyl group, and substituted or unsubstituted heteroarylacyl group;

R 5 is selected from a group consisting of substituted or unsubstituted C 3 -C 10 cycloalkylene group, substituted or unsubstituted C 2 -C 10 heterocyclylene group, substituted or unsubstituted arylene group, and substituted or unsubstituted heteroarylene group;

R 6 and R 7 are independently selected from a group consisting of H, substituted or unsubstituted C 1 -C 6 alkyl group, substituted or unsubstituted C 2 -C 6 alkenyl group, substituted or unsubstituted C 2 -C 6 alkynyl group, substituted or unsubstituted C 3 -C 10 cycloalkyl group, substituted or unsubstituted C 2 -C 10 heterocyclic group, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, substituted or unsubstituted C 1 -C 8 acyl group, substituted or unsubstituted arylacyl group, and substituted or unsubstituted heteroaryl acyl,

or R 6 and R 7 , together with N atom to which R 6 and R 7 are connected, form a substituted or unsubstituted 3 to 10-membered monocyclic or bicyclic structure,

wherein a group is substituted means that the group is substituted by a substituent selected from OH; NH 2 ; C 1 -C 10 alkyl, alkenyl or alkynyl group; C 1 -C 10 alkylamine group; sulfhydryl group; C 1 -C 10 alkylsulfhydryl group; C 1 -C 20 alkoxy group; C 1 -C 10 carbonyl group; C 3 -C 10 cycloalkyl group; 3 to 10-membered heterocyclic group with one or more heteroatoms selected from N, S, O and P; C 6 -C 20 aryl group; C 2 -C 20 heteroaryl group; nitrocyano; and halogen.

2 . The compound, stereoisomer or tautomer thereof according to claim 1 , wherein the compound is represented by Formula II:

3 . The compound, stereoisomer or tautomer thereof according to claim 1 , wherein the compound is represented by Formula III:

4 . The compound, or a salt, stereoisomer or tautomer thereof according to claim 1 , wherein the compound is represented by Formula IV:

5 . The compound, or a salt, stereoisomer or tautomer thereof according to claim 1 , wherein the compound is shown below:

6 . The compound, or a salt, stereoisomer or tautomer thereof according to claim 1 , wherein the compound is shown below:

7 . A compound, or a salt, stereoisomer or tautomer thereof, wherein the compound is shown below:

wherein R 8 is H or a protecting group.

8 . The compound, or a salt, stereoisomer or tautomer thereof according to claim 7 , wherein the compound is shown below:

9 . The compound, or a salt, stereoisomer or tautomer thereof according to claim 7 , wherein the compound is shown below:

or

10 . A pharmaceutical composition, comprising the compound, or a salt, stereoisomer or tautomer thereof according to claim 1 , and optionally a pharmaceutically acceptable carrier.

11 . A pharmaceutical composition, comprising the compound, or a salt, stereoisomer or tautomer thereof according to claim 7 , and optionally a pharmaceutically acceptable carrier.

12 . A method for anesthesia, alleviating pain, improving cognitive function, lung protection, anti-depression, mitigating anxiety and post-traumatic stress syndrome, or treating amyotrophic lateral sclerosis or complex regional pain syndrome of a subject, comprising administrating therapeutic effective amount of the compound, or a salt, stereoisomer or tautomer thereof according to claim 1 to the subject.

13 . The method of claim 12 , wherein the pain comprises chronic pain or neuropathic pain; the depression comprises bipolar depression or major depressive disorder; and improving of cognitive function comprises preventing or treating Alzheimer's, dementia, or Parkinson's disease.

14 . A method for anesthesia, alleviating pain, improving cognitive function, lung protection, anti-depression, mitigating anxiety and post-traumatic stress syndrome, or treating amyotrophic lateral sclerosis or complex regional pain syndrome of a subject, comprising administrating therapeutic effective amount of the compound, or a salt, stereoisomer or tautomer thereof according to claim 7 to the subject.

15 . The method of claim 14 , wherein the pain comprises chronic pain or neuropathic pain; the depression comprises bipolar depression or major depressive disorder; and improving of cognitive function comprises preventing or treating Alzheimer's, dementia, or Parkinson's disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2026
From: SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD.
To: HANGZHOU RUIXI BIOSCIENCE TECHNOLOGY LIMITED COMPANY
Reel/Frame 075542/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2023
From: LI, SHU PENG; ZHOU, QIANG
To: SHENZHEN RUIJIAN BIOTECHNOLOGY CO., LTD
Reel/Frame 062884/0829 →
Continuity (1)
Related Publication 20230303481A1 · Sep 28, 2023
References Cited (40)
US 9650352B2 · Wainer · 2017 [cited by applicant]
US 9867830B2 · Wainer · 2018 [cited by applicant]
US 9963435B2 · Gomez · 2018 [cited by applicant]
US 10738018B2 · Gomez · 2020 [cited by applicant]
US 10919842B2 · Thomas · 2021 [cited by applicant]
US 20140296241A1 · Wainer et al. · 2014 [cited by applicant]
US 20170049780A1 · Wainer et al. · 2017 [cited by applicant]
US 20180057470A1 · Gomez · 2018 [cited by applicant]
US 20180098993A1 · Wainer et al. · 2018 [cited by applicant]
US 20180251435A1 · Gomez · 2018 [cited by applicant]
US 20190135732A1 · Thomas et al. · 2019 [cited by applicant]
US 20190240184A1 · Hashimoto · 2019 [cited by applicant]
US 20200360393A1 · Wainer et al. · 2020 [cited by applicant]
US 20210139411A1 · Thomas · 2021 [cited by applicant]
US 20230192594A1 · Craig · 2023 [cited by applicant]
CN 104395283A · 2015 [cited by applicant]
CN 109311801A · 2019 [cited by applicant]
CN 109475514A · 2019 [cited by applicant]
CN 110167541A · 2019 [cited by applicant]
CN 110218157A · 2019 [cited by applicant]
CN 110559282A · 2019 [cited by applicant]
JP 2015501302A · 2015 [cited by applicant]
JP 2019510768A · 2019 [cited by applicant]
WO 2013056229A1 · 2013 [cited by applicant]
WO 2017165878A1 · 2017 [cited by applicant]
WO 2018079693A1 · 2018 [cited by applicant]
WO 2019169165A1 · 2019 [cited by applicant]
WO 2022041172A1 · 2022 [cited by applicant]
C. G. Wermuth, “The Practice of Medicinal Chemistry”, Telecommunication company, Aug. 15, 1998, p. 235-271, Chapter XIII, 39 pages. [cited by applicant]
Nozaki masakatsu, et al., “The Practice of Medicinal Chemistry”, Chemical company, 1st edition, Jul. 1, 1995, p. 98-99. [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112373, mailed on Jun. 8, 2021, 2 pages. [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112376, mailed on Jun. 2, 2021, 3 pages. [cited by applicant]
Supplementary European Search Report in the European application No. 20950843.1, mailed on Aug. 14, 2023, 7 pages. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112376, mailed on Jun. 2, 2021, 3 pages. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112373, mailed on Jun. 8, 2021, 10 pages. [cited by applicant]
Patrick J. Morris et al. “Synthesis and N-Methyl-D-aspartate (NMDA) Receptor Activity of Ketamine Metabolites” Letter, vol. 19, Aug. 22, 2017 (Aug. 22, 2017). [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112360, mailed on Jun. 16, 2021. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112360, mailed on Jun. 16, 2021. [cited by applicant]
International Search Report in the international application No. PCT/CN2020/112363, mailed on Jun. 2, 2021. [cited by applicant]
English translation of the Written Opinion of the International Search Authority in the international application No. PCT/CN2020/112363, mailed on Jun. 2, 2021. [cited by applicant]